MyMD announces positive Phase 2 topline results for MYMD-1 in sarcopenia/frailty

Q/C TECHNOLOGIES, INC.

Study met primary endpoints: significantly reduced TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) levels.
All pharmacokinetic and secondary safety/tolerability endpoints achieved; no treatment-related adverse events.
Company to present data to FDA and intends to advance MYMD-1 into Phase 3 for sarcopenia.
MYMD-1 is first oral TNF-α inhibitor candidate; potential first FDA-approved drug for sarcopenia if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.